• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and Intracranial Activity of Adagrasib in Patients With -Mutated Non-Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series.

作者信息

Bernstein Ezra, Luo Jia, Wang Kaiwen, Negrao Marcelo V, Jänne Pasi A, Sabari Joshua K

机构信息

Langone Department of Internal Medicine, New York University, New York, NY.

Lowe Center for Thoracic Oncology, Dana-Faber Cancer Institute, Boston, MA.

出版信息

JCO Precis Oncol. 2024 Feb;8:e2300447. doi: 10.1200/PO.23.00447.

DOI:10.1200/PO.23.00447
PMID:38330263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10860949/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/480c/10860949/ce41ec8c7129/po-8-e2300447-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/480c/10860949/0966ff72bf9c/po-8-e2300447-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/480c/10860949/60ecfdf96eb4/po-8-e2300447-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/480c/10860949/ce41ec8c7129/po-8-e2300447-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/480c/10860949/0966ff72bf9c/po-8-e2300447-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/480c/10860949/60ecfdf96eb4/po-8-e2300447-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/480c/10860949/ce41ec8c7129/po-8-e2300447-g003.jpg

相似文献

1
Safety and Intracranial Activity of Adagrasib in Patients With -Mutated Non-Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series.KRYSTAL-1试验中阿达格拉西布治疗KRAS G12C突变的非小细胞肺癌及未经治疗的中枢神经系统转移患者的安全性和颅内活性：病例系列
JCO Precis Oncol. 2024 Feb;8:e2300447. doi: 10.1200/PO.23.00447.
2
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With -Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.KRYSTAL-1 试验中携带 - 突变的未经治疗的中枢神经系统转移的非小细胞肺癌患者的阿达格拉西布颅内疗效。
J Clin Oncol. 2023 Oct 1;41(28):4472-4477. doi: 10.1200/JCO.23.00046. Epub 2023 Jun 16.
3
Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With -Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review.阿巴西布林治疗 Sotorasib 相关肝毒性的 - 突变型非小细胞肺癌患者：病例系列及文献复习。
JCO Precis Oncol. 2024 Apr;8:e2300644. doi: 10.1200/PO.23.00644.
4
Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation.在携带有突变的非小细胞肺癌中使用阿达格拉西布。
N Engl J Med. 2022 Jul 14;387(2):120-131. doi: 10.1056/NEJMoa2204619. Epub 2022 Jun 3.
5
The KRYSTAL-1 study of adagrasib - a new trial for KRAS-mutated non-small-cell lung cancer.阿达格拉西布的KRYSTAL-1研究——一项针对KRAS突变型非小细胞肺癌的新试验。
Nat Rev Clin Oncol. 2022 Nov;19(11):677-678. doi: 10.1038/s41571-022-00676-4.
6
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors (KRYSTAL-1).阿达格拉西布（MRTX849）在晚期实体瘤患者中的首次人体 I/IB 期剂量发现研究（KRYSTAL-1）。
J Clin Oncol. 2022 Aug 10;40(23):2530-2538. doi: 10.1200/JCO.21.02752. Epub 2022 Feb 15.
7
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.阿达格拉西布（MRTX849）在脑转移中的活性：KRASG12C 突变型非小细胞肺癌患者的临床前模型和临床数据。
Clin Cancer Res. 2022 Aug 2;28(15):3318-3328. doi: 10.1158/1078-0432.CCR-22-0383.
8
The KRAS-G12C inhibitor: activity and resistance.KRAS-G12C 抑制剂：活性与耐药性。
Cancer Gene Ther. 2022 Jul;29(7):875-878. doi: 10.1038/s41417-021-00383-9. Epub 2021 Sep 1.
9
Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.肺癌中 KRAS G12C 抑制剂临床耐药时肿瘤/肿瘤微环境生态系统的重塑。
J Clin Invest. 2022 Feb 15;132(4). doi: 10.1172/JCI156891.
10
Acquired Resistance to KRAS Inhibition in Cancer.癌症中对 KRAS 抑制的获得性耐药。
N Engl J Med. 2021 Jun 24;384(25):2382-2393. doi: 10.1056/NEJMoa2105281.

引用本文的文献

1
Adagrasib in the treatment of colorectal cancer.阿达格拉西布用于治疗结直肠癌。
Future Oncol. 2025 Jul 6:1-11. doi: 10.1080/14796694.2025.2524311.
2
Reirradiation using helical tomotherapy-based hypofractionated stereotactic radiotherapy for 19 brain metastases after the second recurrence of distant brain failure: a case report and literature review.基于螺旋断层放射治疗的大分割立体定向放射治疗对远处脑功能衰竭第二次复发后的19例脑转移瘤进行再照射：病例报告及文献综述
Transl Lung Cancer Res. 2025 Jan 24;14(1):272-286. doi: 10.21037/tlcr-2024-1151. Epub 2025 Jan 22.
3
Resistance to KRAS inhibition in advanced non-small cell lung cancer.

本文引用的文献

1
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With -Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.KRYSTAL-1 试验中携带 - 突变的未经治疗的中枢神经系统转移的非小细胞肺癌患者的阿达格拉西布颅内疗效。
J Clin Oncol. 2023 Oct 1;41(28):4472-4477. doi: 10.1200/JCO.23.00046. Epub 2023 Jun 16.
2
Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With -Mutant Non-Small-Cell Lung Cancer.KRAS突变型非小细胞肺癌患者脑转移的发生率及索托拉西布颅内活性的初步证据
JCO Precis Oncol. 2023 Feb;7:e2200621. doi: 10.1200/PO.22.00621.
3
晚期非小细胞肺癌对KRAS抑制的耐药性。
Front Oncol. 2024 May 23;14:1357898. doi: 10.3389/fonc.2024.1357898. eCollection 2024.
Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation.
在携带有突变的非小细胞肺癌中使用阿达格拉西布。
N Engl J Med. 2022 Jul 14;387(2):120-131. doi: 10.1056/NEJMoa2204619. Epub 2022 Jun 3.
4
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.阿达格拉西布（MRTX849）在脑转移中的活性：KRASG12C 突变型非小细胞肺癌患者的临床前模型和临床数据。
Clin Cancer Res. 2022 Aug 2;28(15):3318-3328. doi: 10.1158/1078-0432.CCR-22-0383.
5
Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases.KRAS 基因突变状态对肺癌脑转移免疫治疗疗效的影响。
Sci Rep. 2021 Sep 13;11(1):18174. doi: 10.1038/s41598-021-97566-z.
6
Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation.具有G12C KRAS突变的非小细胞肺癌的临床和影像学特征
Cancers (Basel). 2021 Jul 16;13(14):3572. doi: 10.3390/cancers13143572.
7
A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.回顾性观察性研究 KRAS p.G12C 突变或野生型晚期非小细胞肺癌患者的自然病史。
Lung Cancer. 2021 Sep;159:1-9. doi: 10.1016/j.lungcan.2021.05.026. Epub 2021 May 25.
8
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).KRAS G12C突变的晚期非小细胞肺癌：来自德国前瞻性、观察性、全国性CRISP注册研究（AIO-TRK-0315）的真实世界队列。
Lung Cancer. 2021 Apr;154:51-61. doi: 10.1016/j.lungcan.2021.02.005. Epub 2021 Feb 13.
9
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.KRAS G12C突变阳性非小细胞肺癌的真实世界结局
Lung Cancer. 2020 Aug;146:310-317. doi: 10.1016/j.lungcan.2020.06.030. Epub 2020 Jun 26.
10
Prognostic significance of EGFR and KRAS mutations in NSCLC patients with brain metastases treated with radiosurgery.表皮生长因子受体（EGFR）和 Kirsten 大鼠肉瘤病毒癌基因（KRAS）突变在接受放射外科治疗的非小细胞肺癌脑转移患者中的预后意义
J Radiosurg SBRT. 2015;3(3):171-178.